Researchers from Insilico Medicine and an international group of academic collaborators have applied six independently developed proteomic aging clocks to blood samples from a Phase IIa trial of the AI-designed drug rentosertib, finding that all six models consistently predicted lower biological age in treated patients. The study, published September 7, 2026 in Nature Biotechnology, is the first head-to-head clinical comparison of multiple proteomic aging clocks in a drug intervention…